Exagen Q3 revenue beats analyst expectations

Exagen

04/11/2025 13:08

Overview

Exagen Q3 2025 revenue grows 38% yr/yr, beating analyst expectations

Company reports net loss for Q3 2025 despite revenue growth

Exagen expands AVISE CTD test volume and ASP in Q3 2025

Outlook

Exagen reiterates 2025 revenue guidance of $65 mln to $70 mln

Company expects positive adjusted EBITDA in Q4 2025 if revenue hits high end of range

Result Drivers

AVISE CTD TEST VOLUME - 16% growth in AVISE CTD test volume compared to Q3 2024

ASP INCREASE - Trailing twelve-month ASP for AVISE CTD increased by $37 per test over Q3 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$17.24 mln
$16.90 mln (8 Analysts)
Q3 EPS
-$0.31
Q3 Net Income
-$7.08 mln
Q3 Operating Expenses
$13.17 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Exagen Inc is $12.00, about 1.4% above its November 3 closing price of $11.83

Press Release: ID:nGNX2pS666

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)